Journal
CELLS
Volume 9, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/cells9061511
Keywords
long non-coding RNA (lncRNA); triple-negative breast cancer (TNBC); chemoresistance; acquired drug resistance; oncotherapeutics
Categories
Funding
- Science and Engineering Research Board-Early Career Award (SERB-ECRA), SERB [ECR/2018/000059]
- Department of Science and Technology (DST) International Grant (DST-RBFR) [DST/INT/RUS/RSF/P-29]
- Indian Council of Medical Research (ICMR) [5/13/10/2019/NCD-III]
- Department of Biotechnology (DBT) under its Ramalingaswami Fellowship, Government of India [BT/RLF/Re-entry/24/2014]
- Science and Engineering Research Board (SERB), Government of India [ECR/2016/001519]
- Shenzhen Development and Reform Commission Subject Construction Project [(2017)1434]
- Junior Research Fellowship (SERB-ECRA)
Ask authors/readers for more resources
Triple-negative breast cancer (TNBC) is one of the most lethal forms of breast cancer (BC), with a significant disease burden worldwide. Chemoresistance and lack of targeted therapeutics are major hindrances to effective treatments in the clinic and are crucial causes of a worse prognosis and high rate of relapse/recurrence in patients diagnosed with TNBC. In the last decade, long non-coding RNAs (lncRNAs) have been found to perform a pivotal role in most cellular functions. The aberrant functional expression of lncRNAs plays an ever-increasing role in the progression of diverse malignancies, including TNBC. Therefore, lncRNAs have been recently studied as predictors and modifiers of chemoresistance. Our review discusses the potential involvement of lncRNAs in drug-resistant mechanisms commonly found in TNBC and highlights various therapeutic strategies to target lncRNAs in this malignancy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
